tbuckley/cabot-search huggingface dataset:
Occupational skin cancer induced by ultraviolet radiation and its prevention
Authors: T.L. Diepgen, M. Fartasch, H. Drexler, J. Schmitt
Journal: British Journal of Dermatology (2012)

Skin cancer is by far the most common kind of cancer diagnosed in many western countries and ultraviolet radiation is the most important risk factor for cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Although employees at several workplaces are exposed to increased levels of UV radiation, skin cancer due to long-term intense occupational exposure to UV radiation is often not considered as occupational disease. The actually available evidence in the epidemiological literature clearly indicates that occupational UV radiation exposure is a substantial and robust risk factor for the development of cutaneous SCC and also clearly shows a significant risk for developing BCC. There is enough scientific evidence that outdoor workers have an increased risk of developing work-related occupational skin cancer due to natural UV radiation exposure and adequate prevention strategies must be implemented. The three measures which are successful and of particular importance in the prevention of nonmelanoma skin cancer in outdoor workers are changes in behaviour regarding awareness of health and disease resulting from exposure to natural UV radiation, protection from direct UV radiation by wearing suitable clothing, and regular and correct use of appropriate sunscreens.
Abstract 1752: Search for effective therapies for canine and human osteosarcoma using novel therapeutic agents
Authors: Yating Yang, Ewa Bartczak, Vilma Yuzbasiyan-Gurkan
Journal: Cancer Research (2014)

Abstract Osteosarcoma (OS) is the most common primary bone tumor of both humans and dogs. Despite advances in treatment of other cancers, the survival rates for OS have stagnated for the past decades. Therefore, there is a great need to identify novel and effective treatments. Several classes of novel small molecules with anti-tumor activities have become available in the last few years. Among these are tyrosine kinase inhibitors (TKIs) which are a class of potential anti-tumor medications that are able to inhibit kinase activity of many receptor tyrosine kinases. Another class of molecules target inhibition of the proteasome which induces cell death through various mechanisms. We hypothesized that one or more of such drugs would be effective against canine and human OS cell lines. Our preliminary data identified three TKIs (sunitinib, sorafenib, gefitinib), and a proteasome inhibitor (bortezomib) as having good growth inhibition effects in low concentrations on three canine OS cell lines (D17, Abrams, and Gracie) and two human OS cell lines (SAOS2 and U2OS) in a series of drug screening assay. We then determined the exact IC50 concentration of each drug, capable of inhibiting proliferation by 50%. The IC50 values of bortezomib range from 0.01 to 0.22 μM and the values for sorafenib were from 6 to nearly 9 μM across different cell lines tested, which were all within or close to achievable plasma concentration and tolerable levels. In addition, sunitinib, sorafenib, and bortezomib were shown to decrease cell migration ability in the wound healing assay. With the promising results from in vitro studies, these small molecule inhibitors are good candidates for further evaluation in treating human and canine OS. Citation Format: Yating Yang, Ewa Bartczak, Vilma Yuzbasiyan-Gurkan. Search for effective therapies for canine and human osteosarcoma using novel therapeutic agents. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1752. doi:10.1158/1538-7445.AM2014-1752
Monthly measurements of indoor allergens and the influence of housing type in a northeastern US city
Authors: G.L. Chew, K.M. Higgins, D.R. Gold, M.L. Muilenberg, H.A. Burge, D.R. Gold
Journal: Allergy (1999)

We examined seasonal variation of dust-mite (Der f 1 and Der p 1), cat (Fel d 1), and cockroach (Bla g 1) allergens in Boston, while adjusting for other covariates. Limited data are available on seasonal patterns of indoor allergen concentrations for different geographic regions in the USA. Understanding within-home seasonal variation of allergens is important epidemiologically and clinically.From June 1995 to June 1996, dust samples were vacuumed monthly from the bed, bedroom floor, and kitchen of 20 homes. Indoor temperatures were measured monthly and used in calculating relative and absolute humidity. Monthly home characteristics questionnaires were completed by an adult resident of each home. Dust samples were assayed by enzyme-linked immunosorbent assays.Der f 1 and Der p 1 in beds and floors peaked in the autumn months, Fel d 1 peaked in winter and spring, and Bla g 1 was highest in summer. Dust-mite allergen concentrations were 1.9-2.4 times higher in autumn than spring, but the levels in beds were 19-31 times higher in houses than those in apartments. Although Fel d 1 levels in beds were 2.4 times higher in spring than summer, homes with cats had levels 224 times higher than those without cats. Similarly, Bla g 1 levels in kitchens were 2.1 times higher in summer than winter, but apartments had levels five times higher than those of houses.Sampling season is a source of within-home dust-mite, cat, and cockroach allergen variation in the northeastern USA. However, the influence of housing type and owning a cat far outweighed the seasonal variation of these indoor allergens.
Neural progenitor cell transduction with AAV serotypes 1 and 4
Authors: Gumei Liu, Robert M. Kotin, John A. Chiorini, Beverly L. Davidson
Journal: Molecular Therapy (2004)

The mucopolysaccharidoses (MPS) and the ceroid lipofuscinoses (NCLs) are devastating childhood onset diseases. Some forms of MPS and all NCLs have a severe CNS component. MPS VII, or beta-glucuronidase deficiency, and late-infantile NCL, or tripeptidyl protease deficiency are due to mutations in mRNAs encoding soluble lysosomal enzymes. Prior work in our laboratory and others' demonstrated that overexpression of beta-glucurondiase or TPP-1 from transduced cells in brain can lead to enzyme activity in non-transduced cells remote from the injection site, and improvements in cellular pathology and behavioral deficits. This occurs through a process called cross-correction. We hypothesized that cross-correction could also occur from gene-corrected endogenous neural progenitor cells (NPCs). Transduction of endogenous NPCs with virus expressing beta-glucuronidase or TPP-1 may allow enzyme secretion at several sites: 1) in the SVZ (with enzyme secreted into the ventricular system); 2) during migration through the corpus callosum (with enzyme secreted along the extensive white matter tracts of the corpus callosum); and 3) from differentiated neurons in the olfactory bulb (OB). We tested AAV1 and AAV4 for their ability to target endogenous neural progenitors. AAV4 vector injected unilateral into the lateral ventricle of adult or P0 C57BL/6 mice resulted in highly specific transduction of ependymal cells along the ventricular wall. Only scattered transgene positive cells were observed in the rostral migratory stream (RMS) and olfactory bulb in tissues harvested from several days to 8 weeks after gene transfer, regardless of injection time. Transgene positive cells did not express neuronal cell marker, indicating that NPCs were not a major target of AAV4 transduction in vivo. In contrast to AAV4, transgene positive migrating neuroblasts and olfactory bulb neurons were obvious after unilateral intraventricular injection of AAV1. However, numbers remained too few to consider AAV1-transduced NPCs as a significant source of recombinant lysosomal enzymes. Thus, transduction of endogenous NPCs with AAV4 does not occur, and with AAV1 is limited, preclude the use of these vectors for therapeutic application via NPCs.
Abstract 15532: Altered Ubiquitination and Stability of Protein Inhibitor of Neuronal Nitric Oxide Synthase in the Paraventricular Nucleus of Chronic Heart Failure Rats: Role of Angiotensin II
Authors: Neeru Sharma, Xuefei Liu, Hong Zheng, Kaushik Patel
Journal: Circulation (2014)

Introduction and Hypothesis: Expression of neuronal nitric oxide synthase (nNOS) is decreased in the paraventricular nucleus (PVN) of rats with chronic heart failure (CHF), however the underlying molecular mechanism/s remain unclear. Recently, we demonstrated, Angiotensin II (Ang II) mediated increase in PIN: protein inhibitor of nNOS (0.76±0.10 Sham vs 1.12±0.09* CHF) which is known to down-regulate nNOS through disruption of active dimers (~60% decrease in dimer/monomer ratio) in the PVN of rats with CHF. Functionally impeded monomeric enzyme is degraded by ubiquitin proteasome system. Interestingly, PIN transcript levels remain unchanged in the PVN in CHF (1.00±0.23 Sham vs. 1.1±0.28 CHF). This observation prompted us to elucidate the molecular mechanism for the accumulation of PIN post-transcriptionally in the PVN in CHF Methods and Results: We used coronary artery ligation model of CHF in rats (6-8 weeks past ligation) and neuronal NG108-15 hybrid cell line. PIN translation was inhibited using cyclohexamide (CHX) for 0-4h after 20h of pretreatment with Ang II in NG108 cells. CHX mediated decrease in PIN expression was ameliorated with Ang II (0.19±0.04 vs 0.41±0.06* 4h). Proteasome inhibitor lactacystin (LC) treatment dramatically elevates PIN level suggesting the involvement of proteasome system in PIN regulation. Immunoprecipitation with ubiquitin antibody showed decrease PIN-Ub conjugates in Ang II-treated cells (1.04 ± 0.05 LC vs. 0.62 ± 0.07* LC AngII). In vitro ubiquitination assay in cells transfected with pCMV-(HA-Ub)8 vector revealed reduction of HA-Ub-PIN conjugates after Ang II treatment (9.2 ± 2.2 LC vs. 4.5 ± 0.6* LC Ang II). Furthermore, there was decreased accumulation of PIN-Ub conjugates in the PVN of CHF rats compared to Sham as revealed by immunohistochemistry. Conclusions: Taken together, our studies revealed that PIN is targeted for rapid degradation by the ubiquitin-proteasome pathway and Ang II delays the rate of degradation resulting in accumulation of PIN. We conclude that post-translational accumulation of PIN, mediated by Ang II, leads to a decrease in the dimeric active form of nNOS as well as protein levels of nNOS, which may lead to reduced nitric oxide resulting in over-activation of sympathetic drive during CHF.
Hypomania: a transcultural perspective
Authors: JULES ANGST, THOMAS D. MEYER, ROLF ADOLFSSON, PETER SKEPPAR, MAURO CARTA, FRANCO BENAZZI, RU-BAND LU, YI-HSUAN WU, HAI-CHEN YANG, CHENG-MEI YUAN, PAOLO MORSELLI, PETER BRIEGER, JUDITH KATZMANN, INES ALICE TEIXEIRA LEÃO, JOSÉ ALBERTO DEL PORTO, DORIS HUPFELD MORENO, RICARDO A. MORENO, ODEILTON T. SOARES, EDUARD VIETA, ALEX GAMMA
Journal: World Psychiatry (2010)

This study examined the transcultural robustness of a screening instrument for hypomania, the Hypomania Checklist-32, first revised version (HCL-32 R1). It was carried out in 2606 patients from twelve countries in five geographic regions (Northern, Southern and Eastern Europe, South America and East Asia). In addition, GAMIAN Europe contributed data from its members. Exploratory and confirmatory factor analyses were used to examine the transregional stability of the measurement properties of the HCL-32 R1, including the influence of sex and age as covariates. Across cultures, a two-factor structure was confirmed: the first factor (F1) reflected the more positive aspects of hypomania (being more active, elated, self-confident, and cogni-tively enhanced); the second factor (F2) reflected the more negative aspects (being irritable, impulsive, careless, more substance use). The measurement properties of the HCL-32 R1 were largely invariant across cultures. Only few items showed transcultural differences in their relation to hypomania as measured by the test. F2 was higher among men and in more severe manic syndromes; F1 was highest in North and East Europe and lowest in South America. The scores decreased slightly with age. The frequency of the 32 items showed remarkable similarities across geographic areas, with two excep-tions: South Europeans had lower symptom frequencies in general and East Europeans higher rates of substance use. These findings support the interna-tional applicability of the HCL-32 R1 as a screening instrument for hypomania.
149. Anti-Idiotypic CDR3 Vaccination Against Chronic B-Cell Lymphoma: DNA Vaccine Strategy
Authors: Monica Rinaldi, Sandra Iurescia, Daniela Fioretti, Emanuela Signori, Simona Cali, Gisella Volpe, Claudia Casnici, Ornella Marelli, Giuseppe Saglio, Giancarlo Tonon, Vito Michele Fazio
Journal: Molecular Therapy (2004)

B-cell lymphomas express tumor-specific immunoglobulin. Its variable region [idiotype (Id)] can be considered a tumor-specific antigen and a target for vaccine immunotherapy. Promising results have been obtained in clinical studies of Id vaccination using Id proteins or naked DNA Id vaccines. Several reports have indicated that the immunodominant epitopes of the clone-specific Ig lie mainly in the CDR3. We have previously demonstrated the possibility of using the short peptide encompassing the CDR3 of immunoglobulin heavy chain (VH-CDR3) as a target for eliciting a tumor specific immune response via DNA-based vaccination. DNA immunization of outbred mice with different patient-derived VH-CDR3 peptides elicited antibodies able to recognize native antigens on individual patient's tumor cells. In the present study, we evaluated the humoral and cellular immune response recruited by VL-CDR3-directed DNA vaccines using the murine 38C13 B-cell lymphoma tumor as a model system. The nucleic acid sequence of the idiotypic IgM (38C-Id) light chain was analyzed and the region corresponding to the CDR3 sequence was chosen for the production of a synthetic mini-gene. A high-level expression bicistronic plasmid DNA vaccine was designed to express both the short VL-CDR3 and the mouse IL-2 sequences. IL-2 was chosen as immunomodulating cytokine to enhance T cell-mediated immune response, to improve antigen-specific T cell proliferation, differentiation and Ig secretion of antigen-activated B cells. Vaccination of syngenic C3H/HeN mice with the described plasmid DNA vaccine was found to generate an immune response to the 38C13 tumor, inducing both specific circulating antibodies and specific cytotoxic T-cell (CTL) activity. Combined, our data indicates that a novel CDR3-based DNA vaccine can be improved and used to develop a protective vaccine against B-cell lymphoma. We have recently developed multiple complementary strategies to enhance the efficacy of a CDR3-based DNA vaccine. The first utilizes in vivo electroporation to increase the uptake of vaccine given intramuscularly and to yield powerful humoral and cellular responses. The second one entails the use of plasmid containing a DNA nuclear targeting sequence. The combination of both approaches has been reported to increase plasmid DNA vaccine delivery and expression, thus improving the antigen dose achievable in vivo. The third imply the use of a pathogen-derived sequence, proven to be potent adjuvants for several different DNA vaccines when fused to the tumor antigen in the expression vector. Lastly, we have developed a DNA vaccine encoding artificial strings of defined epitopes. The efficacy of the fusion gene vaccine and the epitope string DNA vaccine, in term of anti-idiotypic response and protection against B-cell lymphoma, will be tested and evaluated.
SeeDNA: A Visualization Tool for K-string Content of Long DNA Sequences and Their Randomized Counterparts
Authors: Junjie Shen, Shuyu Zhang, Hoong-Chien Lee, Bailin Hao
Journal: Genomics Proteomics & Bioinformatics (2004)

An interactive tool to visualize the K-string composition of long DNA sequences including bacterial complete genomes is described. It is especially useful for exploring short palindromic structures in the sequences. The SeeDNA program runs on Red Hat Linux with GTK+ support. It displays two-dimensional (2D) or one-dimensional (1D) histograms of the K-string distribution of a given sequence and/or its randomized counterpart. It is also capable of showing the difference of K-string distributions between two sequences. The C source code using the GTK+ package is freely available.
Inhibition and Reversal by β-Retinoic Acid of Hyperplasia Induced in Cultured Mouse Prostate Tissue by 3-Methylcholanthrene or N -Methyl- N′ -nitro- N -nitrosoguanidine 2
Authors: Dharam P. Chopra, Lee J. Wilkoff
Journal: JNCI Journal of the National Cancer Institute (1976)

The effect of beta-retinoic acid (RA) on carcinogen-induced hyperplasia was studied in organ cultures of mouse prostate gland. 3-Methylcholanthrene (MCA), requiring metabolic activation, or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), not requiring activation, were used to induce hyperplastic changes. Treatment of cultures with MCA or MNNG stimulated cell proliferation and caused the alveolar epithelium to become hyperplastic. The development of this hyperplasia was inhibited when RA was added simultaneously with MCA or MNNG. However, RA had no significant effect on cell proliferation in untreated control cultures. Elimination of carcinogen from the hyperplastic cultures after 8 days of treatment did not reverse hyperplasia of the alveolar epithelium. When the withdrawal of MCA or MNNG was followed by treatment of the cultures with RA, hyperplasia was markedly reversed within 96 hours. Thus RA actively inhibited and reversed the effect of MCA and MNNG, two carcinogens that may have different mechanisms of action.
Abstract 2545: Histamine dihydrochloride and interleukin-2 for relapse prevention in AML: Initial results of the Re:MISSION phase IV trial
Authors: Anna Martner, Anna Rydström, Rebecca Riise, Johan Aurelius, Mats Brune, Kristoffer Hellstrand, Fredrik Bergh Thorén
Journal: Cancer Research (2014)

Abstract BACKGROUND AND METHODS. Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) has been approved within the EU for relapse prevention in the post-consolidation phase of acute myeloid leukemia (AML) (Blood 108:88). We have performed a phase IV trial (Re:MISSION) to assess the immunomodulatory properties of this regimen and to correlate potential biomarkers of immunity with outcome. Eighty-nine patients (age 19-80) with AML in first complete remission received HDC (0.5 mg sc bid) and human recombinant IL-2 (1MIU sc bid) in ten repeated three-week cycles for 18 months or until relapse. Mononuclear cells were analyzed for NK and T cell phenotypes by flow cytometry at onset and during cycles 1 and 3. INDUCTION OF NK CELLS AND NCR EXPRESSION DURING THERAPY. Treatment with HDC/IL-2 resulted in a 3-fold expansion of both CD56bright (CD56/CD16-) and CD16+ (CD56+/CD16+) NK cells during cycle 1 (CD56+, P= 10-6, n=47; paired samples t-test). During cycle 1, the median expression intensity of the natural cytotoxicity receptors (NCRs) NKp46 and NKp30 on CD16+ NK cells increased by 50% and 30%, respectively (P=6 x10-8 for NKp46; P=2 x10-7 for NKp30, n=56). For CD56bright cells, the results were discordant for the NCRs with pronounced induction of NKp30 (P=4 x10-13) during cycle 1 but no induction of NKp46 (P=0.51, n=56). ROLE OF NCR EXPRESSION FOR MAINTENANCE OF REMISSION. An interim analysis of immune markers vs. relapse-free survival (RFS) revealed a strong impact of NK cell NKp46 expression. Patients with NKp46 expression above the median after one 21-day cycle of HDC/IL-2 thus showed significantly higher RFS than those with lower expression (CD16+, P=0.003, HR=3.0, CI 1.4-6.4; CD56bright, P=0.002, HR=3.3, CI: 1.5-7.0; logrank test). High NK cell expression of NKp46 after a treatment cycle also identified a population of elderly patients (&amp;gt;60 years old) with favorable outcome (CD16+, P=0.002, HR=4.1, CI: 1.6-10.2; logrank test). We observed a pronounced expansion of CD4+/CD25+/Foxp3+ regulatory T cells during cycles that did not impact on relapse risk. CONCLUSION. These results highlight the role of NK cells and NCR expression for relapse-free survival in AML. Citation Format: Anna Martner, Anna Rydström, Rebecca Riise, Johan Aurelius, Mats Brune, Kristoffer Hellstrand, Fredrik Bergh Thorén. Histamine dihydrochloride and interleukin-2 for relapse prevention in AML: Initial results of the Re:MISSION phase IV trial. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2545. doi:10.1158/1538-7445.AM2014-2545
Suitability for Psychotherapy
Authors: Harley C. Shands
Journal: Psychotherapy and Psychosomatics (1977)

Research Articles| February 16 2010 Suitability for Psychotherapy. II. Unsuitability and Psychosomatic Disease: II. Unsuitabilíty and Psychosomatic Disease Subject Area: Psychiatry and Psychology Harley C. Shands Harley C. Shands New York Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1977) 28 (1-4): 28–35. https://doi.org/10.1159/000287041 Article history Published Online: February 16 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Harley C. Shands; Suitability for Psychotherapy. II. Unsuitability and Psychosomatic Disease: II. Unsuitabilíty and Psychosomatic Disease. Psychother Psychosom 31 December 1977; 28 (1-4): 28–35. https://doi.org/10.1159/000287041 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1977Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.